₹228.75
▼ -5.15 -2.20%
17 Jul 2026
NSE Listed
ASM 1Ind-Swift Laboratories Ltd. (INDSWFTLAB)
Volume: 5,62,319Avg Vol 1W: 9,58,837.2Avg Vol 1M: 15,12,815.252W Range:₹87.15₹248.45
Key Ratios
Checked 6h agoMarket Cap₹2,034 Cr
Current Price₹228.75
Previous Close₹233.9
High / Low (52w)₹248.45 / ₹87.15
Volume5,62,319
Avg Vol (1W)9,58,837.2
Avg Vol (1M)15,12,815.2
Stock P/E129.22
Book Value₹159.17
Dividend Yield0%
ROE357.5%
ROA246.9%
Revenue (TTM)₹643 Cr
Revenue Growth-67.1%
Profit Margin6.61%
Total Debt₹8 Cr
Shares Outstanding9 Cr
Face Value₹10
EPS (TTM)₹5.69
P/B1.47
Debt / Equity0.02
50 DMA₹181.9
200 DMA₹133.38
Day change-2.20%
SurveillanceASM 1 (as of 2026-07-16)
Price Chart
₹228.75▲ 113.47% · 1Y
2025-07-172026-07-16
20-day avg volume: 15.1L shares
Pros
- Healthy return on equity of 357.5%.
- Company is almost debt-free.
Cons
- Stock trades at a high P/E of 129.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33 Cr | ₹12 Cr | ₹129 Cr | ₹138 Cr | ₹153 Cr | ₹153 Cr | ₹151 Cr | ₹170 Cr |
| EBITDA | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹-12 Cr | ₹12 Cr | ₹12 Cr | ₹23 Cr | ₹15 Cr |
| Net Profit | ₹1 Cr | ₹0 Cr | ₹-5 Cr | ₹222 Cr | ₹9 Cr | ₹8 Cr | ₹10 Cr | ₹15 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹784 Cr | ₹794 Cr | ₹813 Cr | ₹914 Cr | ₹1,082 Cr | ₹1,241 Cr | ₹1,326 Cr | ₹643 Cr |
| EBITDA | ₹66 Cr | ₹59 Cr | ₹88 Cr | ₹118 Cr | ₹108 Cr | ₹205 Cr | ₹246 Cr | ₹38 Cr |
| Net Profit | ₹22 Cr | ₹29 Cr | ₹-21 Cr | ₹-3 Cr | ₹-2 Cr | ₹48 Cr | ₹421 Cr | ₹250 Cr |
| EPS | 4.88 | 5.3 | -4.28 | -0.53 | -0.36 | 8.1 | 71.24 | 35.21 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹2,023 Cr | ₹1,924 Cr | ₹1,870 Cr | ₹1,818 Cr | ₹1,801 Cr | ₹1,824 Cr | ₹1,165 Cr | ₹1,438 Cr |
| Total Liabilities | ₹1,470 Cr | ₹1,336 Cr | ₹1,229 Cr | ₹1,215 Cr | ₹1,200 Cr | ₹1,142 Cr | ₹234 Cr | ₹265 Cr |
| Equity | ₹553 Cr | ₹588 Cr | ₹641 Cr | ₹603 Cr | ₹601 Cr | ₹682 Cr | ₹931 Cr | ₹1,173 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹73 Cr | ₹-64 Cr | ₹125 Cr | ₹134 Cr | ₹150 Cr | ₹195 Cr | ₹-163 Cr | ₹-25 Cr |
| Investing | ₹-17 Cr | ₹-12 Cr | ₹-9 Cr | ₹-10 Cr | ₹5 Cr | ₹-13 Cr | ₹-104 Cr | ₹-110 Cr |
| Financing | ₹-62 Cr | ₹100 Cr | ₹-133 Cr | ₹-124 Cr | ₹-141 Cr | ₹-186 Cr | ₹699 Cr | ₹69 Cr |
| Free Cash Flow | ₹73 Cr | ₹-64 Cr | ₹125 Cr | ₹134 Cr | ₹150 Cr | ₹195 Cr | ₹-163 Cr | ₹-25 Cr |
Shareholding
Promoter 42.99% Institutions 13.88% Public 43.12%
Efficiency & Working Capital
ROCE4.4%
Interest Coverage3
Dividend Payout—
Debtor Days107 d
Inventory Days74 d
Payable Days72 d
Cash Conversion Cycle109 d
Working Capital Days181 d
Shareholding Details
As of 2026-03-31
Promoter43%
FII13.9%
DII0%
Institutions13.9%
Public43.1%
Promoter Pledge0%
No. of Shareholders39,222
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Jul 2025 | Jul 2025 | Aug 2025 | Aug 2025 | Sept 2025 | Dec 2025 | Feb 2026 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 42% | 42% | 40.9% | 40.9% | 36.8% | 36.8% | 39.5% | 39.5% | 39.5% | 39.5% | 43.1% | 43% |
| FIIs | 0.6% | 0.5% | 3.1% | 4.3% | 17% | 17% | 14.9% | 14.9% | 14.8% | 14.3% | 13.8% | 13.9% |
| DIIs | 0.9% | 0.9% | 0.9% | 0.9% | 0.8% | 0% | 0.7% | 0% | 0.7% | 0.7% | 0.2% | 0% |
| Public | 56.4% | 56.6% | 55.1% | 53.9% | 45.5% | 46.2% | 44.9% | 45.6% | 45% | 45.5% | 43% | 43.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 28,883 | 28,752 | 28,117 | 28,709 | 28,907 | 28,907 | 43,984 | 43,984 | 43,780 | 42,121 | 40,404 | 39,222 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Essix Biosciences Limited | Shareholding of Promoter and Promoter Group | 37.9% | 3.29 Cr |
| Hcp Investments | Public Shareholding | 8.6% | 75,00,000 |
| Zeal Global Opportunities Fund | Public Shareholding | 4.6% | 40,13,561 |
| Ashokkumar Chandak | Public Shareholding | 2.7% | 23,44,865 |
| Panchkula Finvest Private Limited | Public Shareholding | 2.4% | 20,91,619 |
| Zaki Abbas Nasser | Public Shareholding | 1.5% | 13,25,000 |
| Pranav Joneja | Public Shareholding | 1.4% | 12,51,400 |
| Sharwan Singh Guleria | Public Shareholding | 1.2% | 10,35,223 |
| N.r. Munjal | Shareholding of Promoter and Promoter Group | 1.2% | 10,12,479 |
| Rishav Mehta | Shareholding of Promoter and Promoter Group | 1.1% | 9,52,357 |
| Rameshkumar Javerchand Jain | Public Shareholding | 1.1% | 9,35,500 |
| S. R. Mehta | Shareholding of Promoter and Promoter Group | 0.6% | 5,38,980 |
| Himanshu Jain | Shareholding of Promoter and Promoter Group | 0.6% | 4,81,256 |
| Gopal Munjal | Shareholding of Promoter and Promoter Group | 0.4% | 3,54,479 |
| V.r. Mehta | Shareholding of Promoter and Promoter Group | 0.4% | 3,41,104 |
| Sunita Jain | Shareholding of Promoter and Promoter Group | 0.4% | 3,17,960 |
| Ravi Mehta | Shareholding of Promoter and Promoter Group | 0.1% | 1,07,170 |
| Neeta Munjal | Shareholding of Promoter and Promoter Group | 0.1% | 98,790 |
| Nidhi Munjal | Shareholding of Promoter and Promoter Group | 0.1% | 87,445 |
| Meenakshi Mehta | Shareholding of Promoter and Promoter Group | 0.1% | 71,746 |
| Annie Mehta | Shareholding of Promoter and Promoter Group | 0% | 26,574 |
| Sahil Munjal | Shareholding of Promoter and Promoter Group | 0% | 25,957 |
| Ishav Mehta | Shareholding of Promoter and Promoter Group | 0% | 9,630 |
| Saurabh Munjal | Shareholding of Promoter and Promoter Group | 0% | 7,755 |
| Bhanavi Mehta | Shareholding of Promoter and Promoter Group | 0% | 7,545 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| N.r. Munjal | 0 | 0% | 2026-03-31 |
| Rishav Mehta | 0 | 0% | 2026-03-31 |
| S. R. Mehta | 0 | 0% | 2026-03-31 |
| Himanshu Jain | 0 | 0% | 2026-03-31 |
| Gopal Munjal | 0 | 0% | 2026-03-31 |
| V.r. Mehta | 0 | 0% | 2026-03-31 |
| Sunita Jain | 0 | 0% | 2026-03-31 |
| Ravi Mehta | 0 | 0% | 2026-03-31 |
| Neeta Munjal | 0 | 0% | 2026-03-31 |
| Nidhi Munjal | 0 | 0% | 2026-03-31 |
| Meenakshi Mehta | 0 | 0% | 2026-03-31 |
| Annie Mehta | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| N R Munjal | Chairman / Executive Director / M D / Promoter | 2025 |
| Himanshu Jain | ED / Joint MD / Promoter | 2025 |
| Rishav Mehta | Executive Director | 2025 |
| Sahil Munjal | Executive Director | 2025 |
| Neerja Chathley | Independent Non Executive Women Director | 2025 |
| Rajinder Kumar Gupta | Independent Non Exe. Director | 2025 |
| SUBODH GUPTA | Independent Non Exe. Director | 2025 |
| Prabhat Khurana | Independent Non Exe. Director | 2025 |
| Pradeep Verma | VP / Company Secretary / Compliance Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Bulk Drugs & Pharmaceuticals | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| In India | ₹150 Cr | 27.4% |
| Outside India | ₹399 Cr | 72.6% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 100 | 67 | 69 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-10 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 17 | 0 | 2 | 0 | 32 | 50 |
| 2025 | 0 | 0 | 0 | 0 | 27 | 27 |
| 2025 | 17 | 0 | 2 | 0 | 4 | 23 |
Insider / Designated-Person Trades
24 recent disclosure(s)
Essix Biosciences LimitedAcquisition · 51,00,000
Essix Biosciences LimitedAcquisition · 25,55,014
Gopal MunjalAcquisition · 2,93,579
Neera MehtaAcquisition · 2,32,057
V.R. MehtaAcquisition · 2,88,204
Sunita JainAcquisition · 2,71,860
Substantial Acquisitions (SAST)
13 disclosure(s)
Pref. Allotment21/07/2025 · 44,85,124
Pref. Allotment02/07/2025 - 23/07/2025 · 18,00,000
Pref. Allotment02/07/2025 · 24,68,000
Pref. Allotment30/08/2024 · —
Market01/04/2024 · 21,72,269
-28/03/2024 · 94,99,720
Company Information
Incorporated1995
ChairmanN R Munjal
AuditorRattan Kaur & Associates
Investor Email[email protected], [email protected]
📍 SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search